Skip to main content
Memory Care Locations

How AI Is Changing Dementia Diagnosis: What Families Should Know

Published on September 1, 2026

Two women sitting together in a clinic waiting area

The Three and a Half Years Before Anybody Says the Word

You probably noticed it first. A question asked twice in one afternoon. A bill paid late by someone who has never paid a bill late. A wrong turn on a road they have driven for thirty years.

Then comes the part nobody warns families about: the waiting. You mention it at the next appointment and hear that a little forgetfulness is normal at this age. You mention it again six months later. Somewhere in there your loved one starts avoiding the phone, and you start keeping a private tally you have not told your siblings about.

That stretch has now been measured. A 2025 systematic review from University College London pooled 13 studies across Europe, the United States, Australia, and China, covering more than 30,000 people, and found it takes an average of 3.5 years from the first noticed symptom to a formal dementia diagnosis. For people under 65, the average was 4.1 years.

Meanwhile, the headlines say artificial intelligence can now identify nine kinds of dementia from a single brain scan. Both things are true at once, and the gap between them is the most useful thing a family can understand right now. This guide covers what the new tools actually do, which ones you can get today, what they will never replace, and how to compress your own three and a half years.

Summary card: AI and Dementia Diagnosis in 2026

What the Mayo Clinic Tool Actually Does

The tool behind the headlines is called StateViewer, developed at Mayo Clinic and published in Neurology on June 27, 2025. The work was led by Dr. David Jones, director of Mayo Clinic’s Neurology Artificial Intelligence Program, with data scientist Leland Barnard.

It reads one specific kind of image: an FDG-PET scan, which shows how the brain is using glucose for energy. Different diseases starve different regions, and those patterns are the fingerprint. StateViewer compares a patient’s scan against a library of cases with confirmed diagnoses and returns color-coded brain maps showing which regions drove its answer, so the clinician can see the reasoning rather than take a verdict on faith.

MRI brain scan displayed on a computer screen
Photo: "Intricate MRI brain scan displayed on a computer screen for medical analysis and diagnosis." by MART PRODUCTION on Pexels

The numbers are genuinely striking. Tested against more than 3,600 scans from people with confirmed dementia and people with normal cognition, the tool identified the dementia type in 88 percent of cases. Clinicians using it reached a diagnosis nearly twice as fast and with up to three times greater accuracy than with standard workflows.

Here is the part the headlines skip. StateViewer is not in clinical use. Mayo’s researchers said plainly that they plan to expand its use and keep evaluating how it performs across different clinical settings. You cannot ask for it at your mother’s appointment next week, and a clinic that offers you something by that name is not offering you what was published. Treat it as a preview of where scan interpretation is heading over the next several years, not as an option on this year’s menu.

Why Naming the Type Is Worth This Much Effort

Families often assume the subtype is a technicality, a Latin label for the same sad road. It is not. The type changes what happens next, sometimes urgently.

In Lewy body dementia, the antipsychotic medications routinely used to manage agitation can trigger severe, occasionally fatal reactions. Getting that label right can be the difference between a calm hospital admission and a catastrophic one. Frontotemporal dementia often arrives as personality and behavior change in someone in their fifties, and gets treated as a psychiatric problem or a marriage problem for years before anyone scans the brain. Vascular dementia turns blood pressure and cholesterol control into active treatment rather than general advice. And an Alzheimer’s diagnosis, confirmed with biomarkers and caught early, is what opens the door to the anti-amyloid drugs.

That is why a tool that separates nine patterns from one scan matters more than a tool that simply says “dementia, yes.” Our guide to the major types of dementia walks through how each one presents and how care has to bend around it.

What You Can Actually Get This Year

Set StateViewer aside. Several AI-assisted and biomarker tools have already cleared the FDA and are in real clinics now. This is the list worth knowing before your next appointment.

Blood tests for Alzheimer’s biology. This is the largest practical shift. Since the FDA cleared the first one in 2025, four blood-based biomarker tests have now been cleared, the most recent being Roche’s Elecsys pTau217 in August 2026, authorized as a single-biomarker tool to help both rule in and rule out amyloid in primary care as well as specialty settings. In studies, these tests have been more than 90 percent accurate at detecting the amyloid and tau changes associated with Alzheimer’s. A blood draw at a regular office now answers a question that used to require a PET scanner or a spinal tap.

AI-scored cognitive assessments. Tablet-based tests such as the Linus Health Core Cognitive Evaluation are FDA-listed and already in use in primary care. Instead of a nurse eyeballing a hand-drawn clock, the software captures how it was drawn, including hesitations and stroke order, and scores signals a human grader cannot see. These run in minutes and fit inside a normal visit, which is exactly where the bottleneck has been.

MRI-based progression scoring. BrainSee, granted FDA authorization in 2024, combines routine brain MRI with cognitive test scores to produce a 0 to 100 score estimating how likely someone with amnestic mild cognitive impairment is to progress to Alzheimer’s dementia within five years. Validation put it around 91 percent accurate. It requires no PET scan and no spinal fluid, and results come back the same day. If your family is sitting inside the uncertainty of an MCI label, this is the category to ask about. Our complete family guide to mild cognitive impairment covers what that stage means and what to do with the window it gives you.

Treatment safety monitoring. Icobrain aria is the first FDA-cleared AI tool for detecting and grading ARIA, the brain swelling and small bleeds that anti-amyloid drugs can cause. It is not diagnostic, but if your loved one starts lecanemab or donanemab, this is the technology watching their MRIs.

One caution on all of it: availability is uneven. Academic medical centers, memory clinics, and large health systems get these first. A rural primary care practice may be years behind, and the tool existing is not the same as the tool being down the road from you.

What AI Does Not Do

Dementia is a clinical diagnosis, and every genuinely useful expert says so first. Under the DSM-5 criteria it means acquired decline in one or more thinking domains together with a decline in daily function. As Dr. Anna Chodos, executive director of Dementia Care Aware, puts it: it is not one blood test, not one imaging study, and not one physical exam. The Alzheimer’s Association said the same thing when the newest blood test cleared, noting that no single test can diagnose Alzheimer’s on its own.

A doctor and an older man talking across a desk

An algorithm reads a pattern. It does not know that your mother’s husband died fourteen months ago, that she has quietly been taking three medications with anticholinergic effects, that her thyroid is off, that her sleep apnea went untreated for a decade, or that her hearing aids have been in a drawer since spring. Every one of those can produce cognitive change that looks like early neurodegenerative disease, and several of them are reversible. A workup that skips the boring bloodwork and goes straight to the impressive scan is a worse workup, no matter how good the scan is.

There is a fairness problem too. These systems learn from the data they were trained on, and much of that data comes from academic centers with populations that do not match the country. A tool validated largely on one group can perform worse on another, which matters most for the families already waiting longest for answers.

And be skeptical of anything sold directly to you. Biomarker tests and imaging belong in the hands of a clinician who will order them for a reason and sit with you while explaining what the result does and does not mean. A number arriving by email with no one to interpret it is not a diagnosis. It is an anxiety generator with a price tag.

How to Compress Your Own Three and a Half Years

Here is the uncomfortable insight buried in the delay research. Almost none of that 3.5 years is spent waiting on a scan to be read. It is spent before anyone orders one. AI is getting very good at the last mile of a journey that mostly stalls at the first. Which means the leverage is yours, and it looks like this.

Write the timeline before the appointment. Dated, specific, factual. “March 14, left the stove on twice in one week.” “June 2, could not find her way back from the pharmacy.” That document does more than any adjective. “Seems worse lately” is easy to file under normal aging. A dated list is not.

A woman writing in a spiral notebook at a table

Go with them. Informant report from someone who has watched the change is a formal part of the assessment, not a courtesy. The person in the chair frequently cannot see what you can see.

Use the Medicare visit you already have. Detection of cognitive impairment is a required element of the Annual Wellness Visit, and there is a separate, billable cognitive assessment and care plan service for when concern is established. You are asking for something the system is already built and paid to do.

Say the sentence out loud. “I am asking for a cognitive evaluation today, and I would like my concerns documented in the chart.” Documentation creates a record, and a record creates a trail that the next appointment has to reckon with.

Ask for the reversible causes to be ruled out by name. Thyroid function, vitamin B12, medication review, depression screening, sleep assessment, and a hearing check. If the visit did not include most of that, you had a screening, not a workup.

Ask directly about a blood biomarker test. The question is simply whether it is appropriate here, and who will interpret the result with you. In 2026, that is a reasonable thing for a family to raise in primary care.

Escalate on the second deferral. If you have been told twice to watch and wait, ask for a referral to a memory clinic, a neurologist, or a geriatrician. Academic Alzheimer’s centers run the most thorough workups and are the places where the newest tools land first. The Alzheimer’s Association 24/7 Helpline (800.272.3900) will help you find what exists near you, at any hour.

Bring in a geriatric care manager or a social worker once care decisions enter the picture. They know your local system in a way no search result does, and they are the right professionals for placement and level-of-care questions.

What This Comes Down To

AI is going to make dementia diagnosis faster, more precise, and more equal in quality between a major medical center and an ordinary clinic. That is worth being genuinely hopeful about. StateViewer’s 88 percent on nine dementia types is a real result from a real journal, and the blood tests are already changing what a primary care office can answer in a week.

But the technology only starts working once someone decides to look. The delay this research measured is a human one made of dismissed symptoms, fear, stigma, and short appointments, and no algorithm reaches back through that. What reaches back through it is a family member with a dated list who declines to be reassured.

And be gentle with yourself about wanting the answer at all. Pushing for a diagnosis can feel like hurrying toward the worst news of your life, and many families find that naming the thing starts a grief that has no funeral attached to it. Our piece on the ambiguous loss families carry is about exactly that feeling. An earlier answer does not make the road shorter. It makes more of the road yours: time to try treatments while they still help, time to sign documents while capacity is not in question, and time to plan while your loved one can still tell you what they want. Our guide to living alone with early-stage dementia covers how to use that window well.

Nothing here is a diagnosis, and no tool in this article is one either. Only a neurologist or geriatrician can tell you what is happening to a specific person. Your job is simply to get them in the room sooner.

Summary card: Bottom Line, Getting a Faster Answer

Sources

Further reading